Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year ...

Wall Street indices closed mixed on Monday. Moody's downgraded the U.S. credit rating due to rising debt. S&P 500 marked its ...

Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction ...

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this ...

The FTSE 100 , US markets and European stocks floundered on Monday, despite a new deal struck between the EU and UK, as ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will acquire 23andMe for a purchase price of $256 million.

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment ...

Regeneron Commits to Comply with Company's Privacy Policy and All Applicable Law; No Changes to 23andMe's Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...

Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.